Sacubitril/Valsartan Safe, effective for HFpEF patients undergoing MHD
Global improvement in cardiac function was observed after treatment with sacubitril/valsartan, as assessed by clinical findings and echocardiographic parameters, in 247 patients on maintenance hemodialysis (MHD) who are also living with heart failure with preserved ejection fraction (HFpEF). Sacubitril is a neprilysin inhibitor and valsartan is an angiotensin II receptor (ARB) antagonist, and drug combination …
Sacubitril/Valsartan Safe, effective for HFpEF patients undergoing MHD Read More »